MarketPulse

TSLP

3 articles
BenzingaBenzinga··Vandana Singh

Sanofi's Dual-Action Drug Shows Promise Beyond Lungs in Asthma, Polyp Trials

Sanofi's lunsekimig met primary endpoints in asthma and nasal polyp trials but failed dermatitis goals, showing favorable safety across all studies.
SNYUPBREGNGSKatopic dermatitisPhase 2 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Lunsekimig Clears Key Phase 2 Hurdles in Asthma and Sinus Disease

Sanofi's bispecific antibody lunsekimig met primary endpoints in phase 2 asthma and chronic rhinosinusitis studies, though atopic dermatitis trial missed targets.
SNYchronic rhinosinusitis with nasal polypsatopic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aclaris Advances Dual-Target Antibody into Asthma Study Following Dermatitis Trial Launch

Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.
ACRSclinical developmentatopic dermatitis